Target family: Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase (type: catalytic_receptor)
Target: Guanylyl cyclase, &alpha;<sub>1</sub>&beta;<sub>1</sub>

Ligand: YC-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): YC-1, a novel activator of platelet guanylate cyclase.
Published in: Blood

Ligand: YC-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme.
Published in: EMBO J

Ligand: YC-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Functional properties of a naturally occurring isoform of soluble guanylyl cyclase.
Published in: Biochem J

Ligand: vericiguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: EMA & FDA (2021)
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
Published in: J Med Chem

Ligand: runcaciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).
Published in: J Med Chem

Ligand: riociguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity:  -
Reference (Journal): NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Published in: Handb Exp Pharmacol

Ligand: riociguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (2013), EMA (2014)
Primary target: no
Median affinity:  -
Reference (Journal): NO-independent regulatory site on soluble guanylate cyclase.
Published in: Nature

Ligand: praliciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 6.570000171661377 pEC50
Reference (Journal): Pharmacological Characterization of IW-1973, a Novel Soluble Guanylate Cyclase Stimulator with Extensive Tissue Distribution, Antihypertensive, Anti-Inflammatory, and Antifibrotic Effects in Preclinical Models of Disease.
Published in: J Pharmacol Exp Ther

Ligand: olinciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential.
Published in: Nitric Oxide

Ligand: NS 2028 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Characterization of NS 2028 as a specific inhibitor of soluble guanylyl cyclase.
Published in: Br J Pharmacol

Ligand: NO (Inorganic)
Interaction type: Activator
Action: Activation
Ligand approved: yes
Approval source: FDA (1999), EMA (2001)
Primary target: yes
Median affinity:  -

Ligand: cinaciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle.
Published in: Br J Pharmacol

Ligand: BAY412272 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): NO-independent regulatory site on soluble guanylate cyclase.
Published in: Nature

Ligand: ataciguat (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase.
Published in: Mol Pharmacol